Leukovac Tablet 100 mg (Imatinib Mesylate)

Adult dose

For adult patients with chronic myeloid leukemia (CML), the recommended dose is 400mg once daily in the chronic phase with Philadelphia chromosome-positive disease. For the accelerated or blast phase, the recommended dose is 600mg once daily. For adult patients with gastrointestinal stromal tumors (GIST), the recommended dose is 400mg daily. For myelodysplastic/myeloproliferative diseases, the recommended dose is 400mg daily. For hypereosinophilic syndrome/chronic eosinophilic leukemia, the recommended dose is 100mg daily, which may be increased to 400mg daily. For recurrent or metastatic dermatofibrosarcoma protuberans, the recommended dose is 800mg daily (take 400mg twice daily). Take with a meal and plenty of water. The 400mg or 600mg dose is taken once daily; the 800mg dose is taken as 400mg twice daily.

Child dose

For pediatric patients with chronic myeloid leukemia, the recommended dose is 340mg/m2 daily based on body surface area. The total daily dose should not exceed 600mg. It may be administered once daily or in 2 divided doses, in the morning and evening. Pediatric patients may take the medicine once daily or, optionally, divide the daily dose into 2 doses taken in the morning and evening.

This drug should not be used by individuals who have hypersensitivity to this drug or any other component. Women who are pregnant or may become pregnant should not take this drug. Additionally, it is recommended that nursing mothers do not take this drug as a safety precaution. This drug should be used cautiously in patients with impaired liver or kidney function, in which case careful monitoring by a physician is required. Patients with a history of heart disease, heart failure, or kidney failure need to exercise special caution when taking this drug, and should seek immediate diagnosis and treatment if symptoms appear. For patients with hypereosinophilia who may have heart problems, it is advisable to undergo cardiac function tests before starting this treatment and to consider steroid therapy if necessary. Patients who take thyroid hormones after thyroid surgery should have their thyroid function checked regularly. In pediatric patients, growth delays have been reported when taking this drug, so growth status should be monitored regularly. Tumor lysis syndrome may occur in patients taking this drug; therefore, dehydration should be corrected before treatment, and appropriate therapy should be provided if uric acid levels are elevated. Patients who are carriers of the hepatitis B virus must undergo viral testing before taking this drug, and should closely monitor for hepatitis reactivation during and after treatment. During the course of taking this drug, abnormalities in liver function, decreased blood cells, gastrointestinal symptoms, skin rashes, edema, fatigue, and other side effects can frequently occur; therefore, any unusual symptoms should be discussed with a physician. Depending on the severity of drug side effects, dosage adjustments or treatment discontinuation may be necessary, and regular health status checks are important during treatment.

• Neutropenia
• thrombocytopenia
• anemia
• headache
• indigestion
• edema
• weight gain
• nausea
• vomiting
• muscle cramps

This drug is sensitive to air and moisture and should be stored in a tightly sealed container. It is important to maintain a storage temperature between 1 and 30 degrees Celsius at room temperature to preserve the drug's efficacy.

Appearance

This drug is a round film-coated tablet that is dark yellow to brown in color.

Package unit

60 tablets (10 tablets/PTP*6)